Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

KalVista Pharmaceuticals, Inc. - Common Stock (NQ:KALV)

17.37 +1.14 (+7.02%)
Streaming Delayed Price Updated: 11:26 AM EDT, Mar 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about KalVista Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
News headline image
KalVista Pharmaceuticals Announces Publications in the Journal of Medicinal Chemistry and Xenobiotica for Sebetralstat
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Presents New Patient-Centric Data at 2022 HAEi Global Leadership Workshop
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Expert Ratings for KalVista Pharma ↗
KalVista Pharma (NASDAQ:KALV) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Where KalVista Pharma Stands With Analysts ↗
Analysts have provided the following ratings for KalVista Pharma (NASDAQ:KALV) within the last quarter: 
Via Benzinga
News headline image
Tesla To $370? Plus HC Wainwright Slashes PT On This Stock By 67% ↗
HC Wainwright & Co. cut KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) price target from $48 to $16. KalVista Pharmaceuticals shares fell 1.8% to $5.06 in pre-market trading. 
Via Benzinga
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday ↗
   Losers 
Via Benzinga
News headline image
Why Is KalVista Pharmaceuticals (KALV) Stock Down 50% Today? ↗
KALV stock investors are having a hard day as KalVista Pharmaceuticals just hit the brakes on a crucial clinical study. 
Via InvestorPlace
News headline image
KalVista Shares Plunge After Ending KVD824 HAE Trial Over Elevated Liver Enzymes In Patients ↗
 
Via Benzinga
News headline image
KalVista Pharma: Q1 Earnings Insights ↗
  KalVista Pharma (NASDAQ:KALV) reported its Q1 earnings results on Thursday, September 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  Wednesday saw 127 companies set new 52-week lows. 
Via Benzinga
News headline image
S&P 500 Rises 100 Points; Nasdaq Up 3% ↗
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers 
Via Benzinga
News headline image
Kalvista Crashes Nearly 60% After Adding HAE Drug To The Scrap Heap ↗
The company scrapped its hereditary angioedema drug due to safety issues. 
Via Investor's Business Daily
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 44 companies hit new 52-week lows. 
Via Benzinga
News headline image
Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday. 
Via Benzinga
News headline image
Nasdaq Surges 350 Points; Crude Oil Rises Sharply ↗
U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday. 
Via Benzinga
News headline image
FaZe Holdings, AXT And Some Other Big Stocks Moving Lower On Tuesday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 700 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
News headline image
US Stocks Open Higher As Dow Jumps 550 Points ↗
U.S. stocks traded higher this morning, with the Dow Jones climbing more than 550 points on Tuesday. 
Via Benzinga
News headline image
Why Kalvista Pharmaceuticals Shares Are Down Over 50% ↗
Kalvista Pharmaceuticals Inc (NASDAQ: KALV) shares are trading lower by 52.42% to $6.78 Tuesday morning after the company announced it terminated the KOMPLETE phase 2 clinical trial for KVD824 for the... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
Gainers Avenue Therapeutics (NASDAQ:ATXI) shares moved upwards by 37.7% to $15.85 during Tuesday's pre-market session. The company's market cap stands at $23.3 million. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
Good morning, investor! It's time for a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday! 
Via InvestorPlace
News headline image
KalVista Pharmaceuticals Announces Termination of KVD824 Phase 2 KOMPLETE Trial for Prophylactic Treatment of Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals to Present at the 2022 HAEi Global Leadership Workshop
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports First Fiscal Quarter Results
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From KalVista Pharmaceuticals, Inc.
Via Business Wire
News headline image
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
KalVista Shares Climb As Late-Stage Label Extension Study On Skin Disorder Candidate Kicks-off ↗
KalVista Pharmaceuticals (NASDAQ: KALV) has initiated the KONFIDENT-S open label extension (OLE) study for its ongoing Phase 3 study of sebetralstat for the on-demand treatment of hereditary angioedema... 
Via Benzinga
News headline image
KalVista Pharmaceuticals Announces Initiation of KONFIDENT-S Open Label Extension Study for Sebetralstat in Hereditary Angioedema
From KalVista Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.